Oliver Luxxe Assets LLC Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Oliver Luxxe Assets LLC increased its stake in Catalyst Pharmaceuticals by 106.6%, acquiring an additional 36,280 shares in the first quarter, raising its total ownership to 70,305 shares valued at approximately $1.7 million.
• Institutional investors own 79.22% of Catalyst Pharmaceuticals, highlighting robust interest from large funds in the biopharmaceutical company.
• Catalyst Pharmaceuticals' stock has recently seen fluctuations in analyst ratings, with some firms upgrading to a "strong-buy" while others have downgraded to a "hold."

Oliver Luxxe Assets LLC lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 106.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 70,305 shares of the biopharmaceutical company's stock after purchasing an additional 36,280 shares during the period. Oliver Luxxe Assets LLC owned about 0.06% of Catalyst Pharmaceuticals worth $1,705,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Systematic Financial Management LP purchased a new stake in Catalyst Pharmaceuticals in the first quarter worth about $4,399,000. Advantage Alpha Capital Partners LP raised its position in shares of Catalyst Pharmaceuticals by 53.5% in the 1st quarter. Advantage Alpha Capital Partners LP now owns 20,037 shares of the biopharmaceutical company's stock valued at $486,000 after purchasing an additional 6,987 shares during the last quarter. Martingale Asset Management L P increased its holdings in Catalyst Pharmaceuticals by 1.2% in the 1st quarter. Martingale Asset Management L P now owns 112,317 shares of the biopharmaceutical company's stock worth $2,724,000 after buying an additional 1,350 shares during the period. EntryPoint Capital LLC acquired a new position in Catalyst Pharmaceuticals in the 1st quarter worth approximately $294,000. Finally, Quantbot Technologies LP increased its holdings in Catalyst Pharmaceuticals by 48.4% in the 1st quarter. Quantbot Technologies LP now owns 16,679 shares of the biopharmaceutical company's stock worth $404,000 after buying an additional 5,442 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CPRX. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Wall Street Zen lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Zacks Research lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of "Buy" and an average price target of $33.20.

Insider Buying and Selling

In other news, insider Steve Miller sold 115,000 shares of the business's stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $20.28, for a total transaction of $2,332,200.00. Following the completion of the transaction, the insider directly owned 949,663 shares of the company's stock, valued at approximately $19,259,165.64. The trade was a 10.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David S. Tierney sold 26,000 shares of the business's stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $20.20, for a total value of $525,200.00. Following the transaction, the director directly owned 379,620 shares of the company's stock, valued at approximately $7,668,324. This represents a 6.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 167,894 shares of company stock valued at $3,434,690. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Up 0.7%

NASDAQ CPRX traded up $0.13 during trading on Friday, hitting $20.51. The stock had a trading volume of 248,455 shares, compared to its average volume of 1,307,433. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.00 and a twelve month high of $26.58. The company has a market capitalization of $2.51 billion, a PE ratio of 12.44, a PEG ratio of 0.82 and a beta of 0.70. The firm has a 50 day moving average price of $21.06 and a 200 day moving average price of $22.53.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.